Ascendis Pharma A/S Reports First Quarter 2022 Financial Results
11 mai 2022 16h01 HE
|
Ascendis Pharma
Phase 3 PaTHway Trial top-line results demonstrated potential of TransCon™ PTH to become the first parathyroid replacement therapy for adults with hypoparathyroidismTransCon PTH U.S. FDA regulatory...
Ascendis Pharma A/S to Participate in the BofA Securities 2022 Healthcare Conference
09 mai 2022 08h00 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, May 09, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company is scheduled to attend the BofA Securities 2022 Healthcare Conference....
Ascendis Pharma A/S Announces First Quarter 2022 Financial Results and Business Update Conference Call on May 11
04 mai 2022 16h05 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, May 04, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) announced today that the company will hold a conference call and live webcast on Wednesday, May 11, 2022 at...
Ascendis Pharma A/S to Present New Endocrinology Results at Four Medical Meetings in May
01 mai 2022 07h00 HE
|
Ascendis Pharma
New data highlights include: - Phase 3 open-label extension study data for growth hormone-deficient children treated for 2.5 years with TransConTM hGH - Initial findings from...
Ascendis Pharma Prices US$500.0 Million Convertible Senior Notes Offering
24 mars 2022 22h41 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, March 24, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product...
Ascendis Pharma Announces Proposed Convertible Senior Notes Offering
23 mars 2022 16h01 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, March 23, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to create new product...
Ascendis Pharma A/S Announces Phase 3 PaTHway Trial of TransCon™ PTH in Adults with Hypoparathyroidism Met Primary and All Key Secondary Endpoints
13 mars 2022 17h53 HE
|
Ascendis Pharma
– For the primary composite endpoint, TransCon PTH demonstrated a response rate of 78.7% compared to 4.8% for control (p-value <0.0001). – TransCon PTH demonstrated statistically significant...
Ascendis Pharma A/S Reports Full Year 2021 Financial Results and Provides a Business Update
02 mars 2022 16h01 HE
|
Ascendis Pharma
- Top-line results from PaTHway, a Phase 3 randomized study evaluating the safety, tolerability, and efficacy of TransCon™ PTH in adult hypoparathyroidism (HP) patients on track for this quarter -...
Ascendis Pharma A/S Announces Full Year 2021 Financial Results and Business Update Conference Call on March 2
25 févr. 2022 08h00 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company will hold a conference call and live webcast on Wednesday, March 2, 2022 at...
Ascendis Pharma A/S to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
10 févr. 2022 16h05 HE
|
Ascendis Pharma
COPENHAGEN, Denmark, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Company is scheduled to participate in the 11th Annual SVB Leerink Global...